Contact
Home • Insights • Developing a gene therapy pricing and access strategy plan

Developing a gene therapy pricing and access strategy plan

Less than 1 min read

The Challenge

Our client, an established biopharma company, needed an early go-to-market pricing and access strategy for their haemophilia B gene therapy.

The Approach

Putnam, an Ashfield Advisory company, was asked to determine the therapy’s value and translate that into an acceptable price point.

The team developed a robust value equation based on stakeholder feedback that was aligned to an estimated price with specific payment models. They also put together a detailed action plan to support market access.

The Results

Following Putnam’s recommendations, the client has begun implementing the plan and is preparing to launch the gene therapy at the proposed price point.

Insights

Other similar insights

See all insights

Creating engaging, compliant risk-management plans

Our client asked Ashfield MedComms to produce risk-management plan manuals targeted at different stakeholder groups.

Read more

Assessing the market for a novel gene therapy

Our client was preparing for the launch of a novel gene therapy and was looking to understand the potential value of its product in the market.

Read more

Creating dedicated customer service and medical information teams

A medical company was looking for a dedicated customer service team and nurse medical information programme to support its gene therapy treatments.

Read more